Moreover, the current work found that treatment with either SGLT2i or GLP1 caused a significant reduction in myocardial fibrosis and myocardial expression of TGF-β, suggesting their antifibrotic activity against DCM via suppression of TGF-β. The gene discussed is GLP1R; the disease is Myocardial fibrosis.